Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Melanoma 9Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Skin Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasm Metastasis 1Klatskin Tumor 1Glioma 1Gastrointestinal Stromal Tumors 1Gallbladder Neoplasms 1Eye Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

selpercatinib 2binimetinib 1Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Thyroid Diseases × binimetinib × Clear all
NCT04913285 2026-04-27

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Pierre Fabre Medicament

Phase 1 Active not recruiting
400 enrolled
DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡